Riskpilot← Back to searchSign inGet full accessXPoll AB
ABActiveOrg 5591618938Norrevångsvägen 56Manufacture of pharmaceutical preparations · NACE 2120Est. 20180 employees
Revenue 2024
SEK 22K
EBITDA margin
-95.5%
+50% vs 2023
Equity ratio
8.1%
Financial strength
Net profit 2024
SEK -21K
+50% vs 2023
| Revenue | SEK 22K | — |
| EBITDA | SEK -21K | +50% |
| Net profit | SEK -21K | +50% |
| Total assets | SEK 334K | -19% |
| Equity | SEK 27K | -44% |
| Employees | 0 | — |
Legal name
XPoll AB
Org number
5591618938
Legal form
Aktiebolag
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
12 juni 2018
Share capital
SEK 51 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva utveckling, tillverkning och försäljning av ingredienser till naturläkemedel, läkemedel och hälsoprodukter samt därmed förenlig verksamhet.
Address
Norrevångsvägen 56
Email
mats.persson@fridsbo.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 335 | 10 765 | 3 839 | 0 | 22 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 156 | 132 | 112 | −42 | −21 |
| Depreciation & amort. | −55 | −55 | −55 | −55 | −55 |
| EBIT | 101 | 77 | 57 | −97 | −76 |
| Net financials | — | −1 | −0 | 0 | — |
| Profit before tax | 11 | 20 | 2 | −42 | −21 |
| Tax | −2 | −4 | −0 | — | −0 |
| Net profit | 9 | 16 | 1 | −42 | −21 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 324 | 6 921 | 727 | 410 | 334 |
| Equity | 73 | 89 | 90 | 48 | 27 |
| Long-term debt | 0 | 0 | — | — | 0 |
| Short-term debt | 1 090 | 6 616 | 366 | 146 | 146 |
| Total debt | 1 090 | 6 616 | 366 | 146 | 146 |
EBITDA margin
-95.5%
This company
15.8%
Market median
-704% vs market
20202024
Equity ratio
8.1%
This company
38.2%
Market median
-79% vs market
20202024
Return on equity
-77.8%
This company
18.4%
Market median
-523% vs market
20202024
Net profit margin
-95.5%
This company
8.1%
Market median
-1279% vs market
20202024
Asset turnover
0.07×
This company
1.12×
Market median
-94% vs market
20202024
Debt / equity
11.37×
This company
0.62×
Market median
-1734% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MO Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of XPoll AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Otto Persson | Chief Executive Officer | 0 companies |
| Jan Åke Harry Trulsson | Board of Directors | 0 companies |
| Gösta Edvard Lilius | Board of Directors | 0 companies |
| Malin Maria Olbe | Chairman | 0 companies |